Compare MLI & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLI | NBIX |
|---|---|---|
| Founded | 1917 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 13.2B |
| IPO Year | 1994 | 1996 |
| Metric | MLI | NBIX |
|---|---|---|
| Price | $112.72 | $131.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 22 |
| Target Price | $130.00 | ★ $176.32 |
| AVG Volume (30 Days) | 532.0K | ★ 825.7K |
| Earning Date | 04-21-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | 29.19 | ★ 41.95 |
| EPS | ★ 6.86 | 4.67 |
| Revenue | ★ $4,178,547,000.00 | $161,626,000.00 |
| Revenue This Year | $10.66 | $22.85 |
| Revenue Next Year | $7.46 | $10.36 |
| P/E Ratio | ★ $16.42 | $28.36 |
| Revenue Growth | 10.87 | ★ 977.51 |
| 52 Week Low | $67.47 | $84.23 |
| 52 Week High | $139.29 | $160.18 |
| Indicator | MLI | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 49.10 | 51.06 |
| Support Level | $108.21 | $124.09 |
| Resistance Level | $119.92 | $136.74 |
| Average True Range (ATR) | 2.57 | 4.05 |
| MACD | 0.68 | 0.46 |
| Stochastic Oscillator | 75.65 | 67.38 |
Mueller Industries Inc makes copper, brass, aluminum, and plastic products. The company reports three business segments: piping systems, industrial metals, and climate. Piping systems, earning majority of the company's revenue, produces tubes, fittings, rods, valves, and other products and operates various firms world-wide. The industrial metals segment manufactures impacts and micro-gauge, brass rod and copper bar products, and brass value-added products. The climate segment produces items used to create temperature-control goods, including valves, twisted tubes, coaxial heat exchangers, and others. Numerous systems use the aforementioned products, including HVAC, water distribution, refrigeration, and automotive.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.